Prostaglandin E1 in peripheral vascular disease: a PET study of muscular blood flow

REFERENCES

• Carlson L, Erikson I. Femoral artery infusion of prostaglandin El in severe peripheral vascular disease. Lancet 1973; I: 155–6.
   Google Scholar
• Carlson LA, Olsson A. Intravenous prostaglandin E in severe peripheral vascular disease. Lancet 1976; II: 810.
   Google Scholar
• Sinzinger H, Virgolini I, O'Grady J. Clinical trials of PGE1, PGI2 and mimetics in patients with peripheral vascular disease. Progr Clin Biol Res 1989; 301: 85–96.
   Google Scholar
• Nakano J, McCurdy JR. Cardiovascular effects of prostaglandin El. J Pharmacol Exp Therap 1967; 156: 538–47.
   PubMedGoogle Scholar
• Sinzinger H, Rogatti W. Prostaglandin El in der Behandlung der peripheren arteriellen Versch-luBkrankheit. Wien Klin Wochenschr 1991; 103: 558–65.
   PubMedGoogle Scholar
• Lambert J, Lambert PJ. Untoward hemodynamic effects of intra-arterial injections of vasodilator drugs on the muscle circulation in the dog hind limb with experimental arterial occlusion. Angiology 1967; 18: 415–27.
   PubMedGoogle Scholar
• Hansteen V, Lorentsen E. Vasodilator drugs in the treatment of peripheral arterial insufficiency. Acta Med Scand 1974; Suppl 556: S3—S62.
   Google Scholar
• Coffman JD. Vasodilator drugs in peripheral vascular disease. N Engl J Med 1979; 300: 713–7.
   PubMed Web of Science ®Google Scholar
• Ranke C, Hendrickx P, Roth U, Brassel F, Creutzig A, Alexander K. Color and conven-tional image-directed Doppler ultrasonography: Accuracy and sources of error in quantitative blood flow measurements. J Chin Ultrasound 1992; 20: 187–93.
   PubMedGoogle Scholar
• Sumner DS. Volume plethysmography in vas-cular disease: an overview. In: Bernstein EF, editor. Noninvasive diagnostic techniques in vas-cular disease. St Louis: Mosby, 1985: 97–118.
   Google Scholar
• Lassen NA, Lindbj erg J, Munck 0. Measurement of blood-flow through skeletal muscle by intra-muscular injection of Xenon-133. Lancet 1964; I: 686–9.
   Google Scholar
• Huang SC, Carson RE, Hoffman EJ, Carson J, MacDonald N, Barrio JR, Phelps ME. Quantita-tive measurement of local cerebral blood flow in humans by positron computed tomography and 15-0-water. J Cereb Blood Flow Metab 1983; 3: 141–53.
   PubMed Web of Science ®Google Scholar
• Bergmann SR, Sobel BE (editors). Positron emis-sion tomography of the heart. Mount Kisco, NY: Futura Publishing Inc., 1992
   Google Scholar
• Strauss LG, Conti PS. The application of PET in clinical oncology. J Nucl Med 1991; 32: 623–48.
   PubMed Web of Science ®Google Scholar
• Bergmann SR, Fox KA, Rand AL, McElvany KB, Welch MJ, Markham J, Sobel BE. Quantification of regional myocardial blood flow in vivo with H2-15-0. Circulation 1984; 70: 724–33.
   Google Scholar
• Burchert W, Schellong SM, van den Hoff J, Meyer GJ, Alexander K, Hundeshagen H. Oxygen-15-water PET assessment of muscular blood flow in peripheral vascular disease. J Nucl Med 1997; 38: 93–8.
   Google Scholar
• Kety SS, Schmidt CE. The nitrous oxide method for the quantitative determination of cerebral blood flow in man: theory, procedure and normal values. J Chin Invest 1948; 27: 476–83.
   PubMed Web of Science ®Google Scholar
• van den Hoff J, Burchert W, Miiller-Schauenburg W, Meyer GJ, Hundeshagen H. Accurate local blood flow measurements with dynamic PET: fast determination of input function delay and dis-persion by multilinear minimization. J Nucl Med 1993; 34: 1770–7.
   PubMedGoogle Scholar
• Pasch AR, Burke A, Ricotta JJ, Wilson G, DeWeese JA. Intraarterial prostaglandin E1 and canine hind limb blood flow. Curr Surg 1983; 40: 289–91.
   Google Scholar
• Lynch TG, Hobson RW, Barbalinardo JP, Kerr JC. Effects of intravenous and intra-arterial in-fusions of prostaglandin E1 on canine hindlimb blood flow distribution. Surgery 1984; 96: 35–41.
   PubMedGoogle Scholar
• Lassen NA, Holstein P. Use of radioisotopes in assessment of distal blood flow and distal blood pressure in arterial insufficiency. Surg Clin North Am 1974; 54: 39–55.
   PubMed Web of Science ®Google Scholar
• Nielsen PE, Nielsen SL, Holstein P, Poulsen HL, Hansen EH, Lassen NA. Intra-arterial infusion of prostaglandin E in normal subjects and patients with peripheral arterial disease. Scand J Chin Lab Invest 1976; 36: 633–40.
   PubMed Web of Science ®Google Scholar
• Brecht T, Ayaz M. Circulation parameters during intravenous and intra-arterial administration of increasing doses of prostaglandin E1 in healthy subjects. Klin Wochenschr 1985; 63: 1201–4.
   PubMedGoogle Scholar
• Hirai M, Nakayama R. Haemodynamic effects of intra-arterial and intravenous administration of prostaglandin E1 in patients with peripheral arterial disease. Br J Surg 1986; 73: 20–3.
   PubMedGoogle Scholar
• Bergstrom S, Duner H, v. Euler US, Pernow B, Sjövall J. Observations on the effects of infusion of Prostaglandin E in man. Acta Physiol Scand 1959; 45: 145–51.
   Google Scholar
• Carlson LA, 065 L. Effect of Prostaglandin E1 on blood pressure and heart rate in the dog. Acta Physiol Scand 1966; 67: 89–99.
   Google Scholar
• Golub M, Zia P, Matsuno M, Horton R. Meta-bolism of prostaglandins A1 and E1 in man. J Clin Invest 1975; 56: 1404–10.
   PubMedGoogle Scholar
• Peskar BA, Cawello W, Rogatti W, Rudofsky G. On the metabolism of Prostaglandin E1 admini-stered intravenously to human volunteers. J Physiol Pharmacol 1991; 42: 327–31.
   PubMedGoogle Scholar
• Anggard E, Larsson C. The sequence of the early steps in the metabolism of prostaglandin El. Eur J Pharmacol 1971; 14: 66–70.
   PubMed Web of Science ®Google Scholar
• Westwick J. The effect of pulmonary metabolites of prostaglandins E1, E2 and F2a on ADP-induced aggregation of human and rabbit platelets. Br J Pharmacol 1976; 58: P297 —P298.
   Google Scholar
• Braun M, Ney P, Hohlfeld T, Szymanski C, Bruch L, Schrör K. Pharmakologie von 13,14-Dihydro-PGE1 im Vergleich zu PGEi. VASA Suppl 1991; 33: 337–8.
   Google Scholar
• Creutzig A, Caspary L, Alexander K. Skin sur-face oxygen pressure fields during administration of prostaglandin E1 in patients with arterial occlu-sive disease. Klin Wochenschr 1990; 68: 207–12.
   Google Scholar
• Hecker G, Ney P, Schrör K. Cytotoxic enzyme release and oxygen centered radical formation in human neutrophils are selectively inhibited by E-type prostaglandins but not by PGI2. Naunyn-Schmiedebergs Arch Pharmacol 1990; 341: 308–15.
   Google Scholar
• Kury PG, Barnwell PW, McConnel HM. The effect of prostaglandin E1 and E2 on the human erythrocyte as monitored by spin labels. Biochem Biophys Res Commun 1974; 56: 478–83.
   Google Scholar
• Emmons PR, Hampton JR, Harrison MJG, Honour AJ, Mitchell JRA. Effect of prosta-glandin E1 on platelet behaviour in vitro and in vivo. Br Med J 1967; 2: 468–72.
   Google Scholar
• Sinzinger H, Virgolini I, Fitscha P. Pathomecha-nisms of atherosclerosis beneficially affected by prostaglandin El—an update. VASA 1989; 28 Suppl: 14–8..
   Google Scholar